RCEL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.06% compare to its pairs and should correct upwards.

Stats
Today's Volume	281 463
Average Volume	287 159
Market Cap	204.33M
EPS	$-0.530 ( Q3 \| 2023-11-09 )
Next earnings date	( $-0.590 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.50 (Sector) 42.63 (Industry) 0
ATR14	$0.0140 (0.18%)

AEMD -13.81%

AFIB -13.41%

AHCO 1.42%

AHPI 0.00%

ALGN -0.65%

ANIK -1.52%

APEN 0.00%

APYX -4.96%

ARAY 1.68%

ATEC 0.58%

AXDX 1.74%

AXGN 0.28%

AXNX -0.25%

AZYO 2.05%

BBLG 0.83%

BIOL 38.50%

BJDX -6.77%

BMRA -2.16%

BRKR -0.61%

BSGM -5.35%

BWAY 0.83%

CERS 0.57%

CFMS 0.44%

CLPT -5.11%

CODX -1.57%

CSII 0.15%

CTKB 1.64%

CTSO -9.00%

CUTR 3.42%

CVRX 2.48%

DCTH 1.70%

DXCM -1.01%

DYNT -20.97%

EAR -4.10%

ECOR -0.16%

EDAP 4.21%

ESTA 3.56%

FONR 1.46%

HJLI -1.98%

HSDT -1.99%

HSKA 0.00%

HYPR -11.00%

IART 1.36%

ICAD 0.00%

ICCM -1.99%

IINN -2.13%

INGN 2.01%

INMD 1.00%

IRIX 0.00%

IRMD -0.05%

IRTC 3.12%

ISO 0.00%

ITMR 0.00%

KIDS -0.10%

LHDX 0.00%

LIVN -0.02%

LNSR 2.74%

LUCD -5.64%

LUNG 2.76%

MASS 0.00%

MDGS 10.28%

MOTS 0.17%

MOVE -3.51%

MSON 0.00%

NAOV -5.41%

NARI 2.47%

NMRD 0.00%

NNOX 10.71%

NPCE 8.00%

NTUS 0.00%

NURO 0.27%

NUVA -2.24%

NUWE 18.57%

NVCN 0.00%

NVNO 1.55%

OBLN -5.86%

OFIX -1.63%

OM -7.00%

PACB 0.74%

PAVM 6.30%

PETV 0.00%

PODD -2.50%

PRCT 2.28%

PROF -4.88%

QIPT 3.54%

QTRX 1.62%

RCEL -0.38%

RPID -4.90%

RSLS -3.23%

RWLK 6.07%

RXST 1.81%

SGHT 1.99%

SIBN 4.02%

SIEN -18.69%

SILK 0.52%

SINT -6.98%

SOLY 0.00%

SRDX 0.17%

SRGA 0.00%

SRTS 1.72%

SWAV 0.00%

TBIO -8.29%

TCMD 3.20%

TELA -8.56%

THMO 9.52%

TIVC -1.02%

TLIS 0.72%

TMCI 0.15%

TMDI 0.00%

TMDX 1.89%

TNDM -0.35%

TNON 0.00%

UFPT 2.41%

VERO -2.71%

VIVE 0.00%

VMD 1.24%

VRAY 0.00%

VREX 0.75%

VVOS -7.11%

XAIR -7.38%

XENT 0.00%

ZIMV 3.75%

Insider Trading

Date	Person	Action	Amount	type
2024-06-05	Panaccio Lou	Buy	9 200	Common Stock
2024-06-05	Panaccio Lou	Buy	3 943	Stock Options (Right to Buy)
2024-06-05	Crowe Suzanne	Buy	9 200	Common Stock
2024-06-05	Crowe Suzanne	Buy	3 943	Stock Options (Right to Buy)
2024-06-05	Cook Jeremy Curnock	Buy	9 200	Common Stock

INSIDER POWER
85.41
Last 98 transactions
Buy: 1 898 967 \| Sell: 352 272

Correlation (AI algo v.1.1b): Undervalued: 0.06% $7.92 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.27 (neutral)

Short: -0.69 (moderate negative)

Signal:(47.384) Neutral

Avita Therapeutics Inc Correlation

10 Most Positive Correlations
LSXMA	0.926
CTSH	0.922
LSXMK	0.922
INVE	0.908
FSV	0.9
BRZE	0.899
ZD	0.892
MBIO	0.892
BMEA	0.888
MPAA	0.884

10 Most Negative Correlations
PAAS	-0.969
AMRK	-0.953
CRIS	-0.932
VERU	-0.922
ABIO	-0.919
HYMC	-0.917
RING	-0.909
CENX	-0.902
FSLR	-0.901
GRIN	-0.898

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Avita Therapeutics Inc Correlation - Currency/Commodity

-0.41
( neutral )

-0.52
( weak negative )

0.00
( neutral )

-0.03
( neutral )

0.00
( neutral )

0.07
( neutral )

Avita Therapeutics Inc Financials

Annual	2022
Revenue:	$34.42M
Gross Profit:	$28.38M (82.45 %)
EPS:	$-1.070

FY	2022
Revenue:	$34.42M
Gross Profit:	$28.38M (82.45 %)
EPS:	$-1.070

FY	2021
Revenue:	$29.23M
Gross Profit:	$23.28M (79.65 %)
EPS:	$-1.170

FY	2020
Revenue:	$14.26M
Gross Profit:	$11.29M (79.16 %)
EPS:	$-2.07

Financial Reports:

No articles found.

Avita Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Avita Therapeutics Inc

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.